Few plant-based products in the United States have generated as much regulatory back-and-forth as kratom and its concentrated derivative, 7-hydroxymitragynine, commonly written as 7-OH. The compound is consumed by an estimated fifteen million Americans, sits in legal gray zones across multiple states, and continues to test the limits of how a federal system handles a substance that one agency wants to schedule, another agency hesitates on, and dozens of state legislatures regulate in conflicting ways.
This guide walks through the federal landscape, the state-by-state picture, the policy debate over 7-OH specifically, and how the American regulatory model compares with the approach taken by countries where the kratom plant originated. The goal is to give readers a clear policy reference, not a verdict.
Federal Position: A Decade of Uncertainty
Kratom, the leaf of Mitragyna speciosa, is not a federally controlled substance in the United States. In 2016, the Drug Enforcement Administration announced an intent to place kratom and its alkaloids on Schedule I as an emergency action. Public response was unusually intense, with more than 142,000 signatures on a White House petition and bipartisan congressional letters questioning the science.
The DEA withdrew the notice within six weeks, an outcome rarely seen for a scheduled drug action. Since then, the federal posture has been one of advisory caution from the Food and Drug Administration rather than active scheduling. The FDA has issued import alerts, seized shipments at the border, and continues to warn consumers about contamination and unregulated potency.
The 2024 to 2025 Shift on 7-Hydroxymitragynine
7-OH occupies a more contested position. Unlike whole-leaf kratom, 7-OH is sold as a concentrated extract in tablets, shots, powders, and vape devices. The FDA in 2024 began signaling concern that these refined products differ enough from traditional kratom to warrant separate consideration. By early 2025, federal officials had repeatedly described high-potency 7-OH products as functionally distinct from the loose-leaf market the Kratom Consumer Protection Act movement was originally built around.
The American Kratom Association, the largest industry advocacy group, has itself drawn a line between unrefined leaf and concentrated 7-OH, calling for additional standards on the latter. This split inside the advocacy community is unusual and reflects how quickly the 7-OH segment has grown.
The Kratom Consumer Protection Act Framework
In the absence of federal regulation, more than a dozen states have passed some version of a Kratom Consumer Protection Act, often shortened to KCPA. The model legislation, originally drafted by industry advocates and amended by state legislatures, generally establishes a minimum age of twenty one for purchase, requires lab testing for contaminants, mandates labeling for alkaloid content, and bans synthetic adulterants.
States that have adopted KCPA-style frameworks include Utah, Arizona, Georgia, Nevada, Oklahoma, Colorado, Missouri, Tennessee, and Virginia, among others. Texas, Florida, and Mississippi have passed partial versions or are debating new bills. Policy researchers generally regard the KCPA approach as a workable middle path, though enforcement varies and standards on 7-OH specifically remain inconsistent.
States Where Kratom Is Banned Outright
Six states ban kratom in all forms for general sale: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. The legal mechanisms differ. Alabama classified kratom alkaloids as Schedule I controlled substances in 2016. Arkansas placed mitragynine on its controlled substance list in 2016 as well. Indiana classifies kratom as a synthetic drug despite its plant origin, a categorization industry groups have challenged in court.
Rhode Island previously had a full ban but has discussed loosening restrictions for users with certain health conditions. Vermont and Wisconsin maintain bans through their state controlled substance laws. Online retailers, including those that sell 7-OH tablets and other concentrated products, generally refuse to ship into these states, treating the ban as binding regardless of the federal posture.
Counties and Cities With Local Restrictions
Beyond outright state bans, several counties and cities maintain their own restrictions on kratom or 7-OH. Sarasota County in Florida has banned kratom since 2014, predating most state-level legislation. San Diego and Oceanside in California have local bans, despite the state itself allowing kratom sale. Alton, Jerseyville, and Edwardsville in Illinois have passed municipal restrictions.
Columbus and Union County in Mississippi have similar local prohibitions. These patchwork rules create compliance challenges for online retailers, who must screen orders not just by state but by zip code. Some sellers maintain visible exclusion lists, while others rely on payment processor restrictions to enforce regional limits automatically at checkout.
States With Age Restrictions or Specific Labeling Rules
A larger category of states allow kratom and 7-OH but require buyers to be at least twenty one, or in some cases eighteen, and impose specific labeling requirements without enacting a full KCPA. New Hampshire requires buyers to be at least eighteen. Tennessee permits kratom for those twenty one and older while having previously had a broader restriction. Illinois prohibits sale to anyone under eighteen and has additional local rules layered on top.
New York debated multiple versions of an age-restriction bill across 2023 to 2025, with the most recent version focusing on labeling and 7-OH disclosure rather than outright prohibition. These middle-ground frameworks reflect the broader political reality that complete bans face strong consumer pushback.
7-OH-Specific Regulations Now Emerging
In 2025 and into 2026, several states began drafting or passing measures aimed specifically at 7-hydroxymitragynine concentrates rather than whole-leaf kratom. Colorado introduced a bill that would set per-serving alkaloid caps for 7-OH products sold in retail outlets. Utah, which already has a KCPA, added clarifying language that 7-OH extracts must list total alkaloid content per unit.
Florida considered separate legislation in 2025 addressing 7-OH vape devices specifically. These targeted measures suggest a policy trend toward distinguishing concentrated derivatives from the leaf, which mirrors how the federal system has historically separated cannabis flower from concentrated extracts. For consumers comparing different formats and brands, lab-tested 7OH Products offer one reference point for what compliant labeling looks like in practice.
How US Policy Compares Internationally?
The American regulatory landscape looks unusual compared with the countries where Mitragyna speciosa is native. Thailand, which had banned kratom since 1943 as part of a colonial-era anti-opium policy, fully legalized the plant in 2021 and removed it from controlled substance schedules. Indonesia, the largest global supplier of kratom leaf used in US imports, has signaled plans to restrict exports starting in 2024, though enforcement has been delayed multiple times.
Malaysia continues to ban kratom under the Poisons Act. The European Union does not regulate kratom at the union level, leaving member states to set their own rules. Several EU members, including Denmark, Latvia, Lithuania, Poland, Romania, and Sweden, treat kratom as a controlled substance. The US position of allowing sale in most states while declining to schedule it federally is closer to the United Kingdom model, which permits kratom under general food and supplement rules.
The FDA and DEA Positioning Going Into 2026
The DEA has not formally revisited scheduling kratom since the withdrawn 2016 notice. The FDA, however, continues to take a more active stance, especially with regard to 7-OH. Public statements from FDA officials in late 2024 and through 2025 emphasized the distinction between whole-leaf kratom and concentrated 7-OH derivatives, with several warning letters issued to vendors of 7-OH vape products.
None of this rises to the level of federal scheduling, but it changes the operational environment in which retailers and manufacturers work. Industry observers expect continued FDA enforcement against unlabeled or contaminated products, while genuine scheduling action against 7-OH would require either new DEA initiative or congressional legislation, neither of which appears imminent at the start of 2026.
What This Means for Consumers and Industry?
The state-by-state nature of US kratom and 7-OH policy creates real costs for both buyers and sellers. Consumers in banned states cannot legally obtain products that are freely sold one hundred miles away. Retailers must maintain compliance systems that block orders by zip code and update them when local rules change.
Lab testing requirements vary by state, which forces national brands to produce certificates of analysis that satisfy the strictest regimes if they want to ship nationally. Industry trade groups continue to push for federal preemption, arguing that a single national standard would protect consumers more effectively than the current patchwork. Opposition to preemption comes from public health groups who view federal action as a slippery slope toward full scheduling.
Outlook and Policy Recommendations
Three trends are likely to define the next eighteen months of kratom and 7-OH policy in the United States. First, more states will pass KCPA-style legislation with specific carveouts for 7-OH products. Second, the FDA will continue targeted enforcement against vendors making unsupported health claims or selling contaminated products, without seeking to schedule the substance. Third, international supply changes, particularly any Indonesian export restrictions, will reshape what products are available domestically.
Policymakers focused on consumer safety would do well to support harmonized labeling standards and mandatory third-party testing, since these measures address the most common cause of adverse events without restricting access for adult consumers who use kratom and 7-OH responsibly. The story is far from settled, but the contours are becoming clearer with each legislative session.
Closing Note
Kratom and 7-OH regulation in the United States is best understood not as a single national policy but as a federalist mosaic shaped by competing concerns about consumer access, public health, and bureaucratic caution. The story will continue to evolve through state legislative sessions, FDA enforcement actions, and international supply shifts. For policy analysts, what matters most is the absence of a coherent federal framework and the resulting variability across jurisdictions.
For ordinary consumers, what matters is knowing exactly where their state stands today and whether the products they buy comply with the standards their legislators have set. This guide should serve as a starting point for both groups as the regulatory landscape continues to take shape over the months and years ahead.
Frequently Asked Questions
Q1. Is kratom legal at the federal level in the United States?
Yes. Kratom is not a federally controlled substance. The DEA proposed scheduling it in 2016 but withdrew the notice. The FDA continues to issue advisory warnings but has not banned the substance.
Q2. How many US states have banned kratom outright?
Six states currently ban kratom for general sale: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Several counties and cities maintain local bans even where state law permits sale.
Q3. What is the Kratom Consumer Protection Act?
The KCPA is a model state law that sets minimum age, lab testing, labeling, and adulterant standards for kratom products. More than a dozen states have passed some version of it.
Q4. Is 7-OH regulated differently from whole-leaf kratom?
Increasingly, yes. Several states are now drafting 7-OH-specific rules covering alkaloid caps, labeling, and vape device restrictions. The FDA has also signaled separate concerns about concentrated 7-OH derivatives.
